Accepted for Publication: November 27, 2013.
Published Online: February 3, 2014. doi:10.1001/jamaneurol.2013.6064.
Study concept and design: Grossman, Elman, McMillan, Hu, Lee, Trojanowski.
Acquisition of data: Grossman, Elman, McCluskey, Boller, Shaw, Irwin, Lee, Trojanowski.
Analysis and interpretation of data: Grossman, McCluskey, McMillan, Boller, Powers, Rascovsky, Shaw, Irwin, Lee, Trojanowski.
Drafting of the manuscript: Grossman, McMillan, Powers, Rascovsky, Lee, Trojanowski.
Critical revision of the manuscript for important intellectual content: Grossman, Elman, McCluskey, McMillan, Boller, Rascovsky, Hu, Shaw, Irwin, Lee, Trojanowski.
Statistical analysis: Grossman, McMillan, Powers, Lee, Trojanowski.
Obtained funding: Grossman, Lee, Trojanowski.
Administrative, technical, or material support: Grossman, McCluskey, Boller, Rascovsky, Shaw, Lee, Trojanowski.
Study supervision: Grossman, Lee, Trojanowski.
Conflict of Interest Disclosures: Dr Hu has filed a provisional patent on the ptau:ttau ratio as a biomarker for FTLD-TDP and ALS through Emory University. No other disclosures were reported.
Funding/Support: This work was supported in part by National Institutes of Health grants AG032953, AG017586, NS044266, AG038490, and AG043503; the ALS Association; and the Wyncote Foundation.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.